Plante Moran Financial Advisors’s Pacira BioSciences PCRX Stock Holding History

Plante Moran Financial Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$381	Buy	+15	New	+$355	﹤0.01%	1220
2018 Q3	–	Sell	-428	Closed	-$14K	–	828
2018 Q2	$14K	Hold	428	–	–	0.01%	514
2018 Q1	$13K	Hold	428	–	–	0.01%	568
2017 Q4	$20K	Hold	428	–	–	0.01%	500
2017 Q3	$16K	Hold	428	–	–	0.01%	488
2017 Q2	$20K	Hold	428	–	–	0.01%	473
2017 Q1	$20K	Hold	428	–	–	0.01%	484
2016 Q4	$14K	Hold	428	–	–	0.01%	535
2016 Q3	$15K	Hold	428	–	–	0.01%	533
2016 Q2	$14K	Hold	428	–	–	0.01%	481
2016 Q1	$23K	Sell	428 -13	-3%	-$760	0.02%	364
2015 Q4	$34K	Buy	441 +291	+194%	+$16.5K	0.03%	361
2015 Q3	$6K	Hold	150	–	–	﹤0.01%	561
2015 Q2	$11K	Hold	150	–	–	0.01%	511
2015 Q1	$13K	Hold	150	–	–	0.01%	477
2014 Q4	$13K	Hold	150	–	–	0.01%	486
2014 Q3	$15K	Hold	150	–	–	0.01%	455
2014 Q2	$14K	Hold	150	–	–	0.01%	442
2014 Q1	$10K	Hold	150	–	–	0.01%	370
2013 Q4	$9K	Sell	150 -100	-40%	-$5.26K	0.01%	472
2013 Q3	$12K	Hold	250	–	–	0.01%	369
2013 Q2	$7K	Buy	+250	New	+$7.23K	0.01%	408

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Plante Moran Financial Advisors's PCRX Position: Q2 2026 in Review

Plante Moran Financial Advisors opened a new position in Pacira BioSciences (PCRX) in Q2 2026: 15 shares worth $381. The stake represents ﹤0.01% of the portfolio and ranks #1220 among its holdings. This is a return to the name: Plante Moran Financial Advisors previously reported a position in PCRX as recently as Q2 2018.

Plante Moran Financial Advisors first reported a position in PCRX in Q2 2013 and has held it in 22 quarters since. The position peaked at $34K in Q4 2015. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Plante Moran Financial Advisors held 15 shares of Pacira BioSciences worth $381 as of Q2 2026.
Pacira BioSciences was a new Plante Moran Financial Advisors position in Q2 2026.
Pacira BioSciences made up ﹤0.01% of Plante Moran Financial Advisors's portfolio in Q2 2026, its #1220 holding.
Plante Moran Financial Advisors first reported a position in Pacira BioSciences in Q2 2013 and has held it in 22 quarters since.
Plante Moran Financial Advisors's Pacira BioSciences position peaked at $34K in Q4 2015.
254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Plante Moran Financial Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.